Company Overview of LoneStar Heart, Inc.
LoneStar Heart, Inc., a biomedical company, develops cardiac restorative therapies for patients with heart failure. It develops a portfolio of device and drug based programs for congestive heart failure. The company develops Algisyl LVR, a self-gelling implantable biopolymer that is implanted in the heart for preventing or reversing the progression of advanced heart failure in patients who have an enlarged left ventricle as a result of a myocardial infarct, mitral valve regurgitation, ischemia, arrhythmias, and other disorders; and Isoxazoles, small molecule drugs for the treatment of heart failure. The company also develops cell reprogramming cardiac fibroblasts for the regeneration of card...
26051 Merit Circle
Laguna Hills, CA 92653
Founded in 2010
Key Executives for LoneStar Heart, Inc.
President, Chief Operating Officer and Director
Founder and Executive Chairman
Founder, Chief Scientific Advisor and Director
Vice President of Clinical & Regulatory Affairs
Compensation as of Fiscal Year 2015.
LoneStar Heart, Inc. Key Developments
LoneStar Heart Receives European Approval to Market its Algisyl-LVR(R) Hydrogel Implant for the Treatment of Advanced Heart Failure
Oct 1 14
LoneStar Heart, Inc. announced that it received the CE Mark (Conformite Europeene) for its Algisyl-LVR(R) hydrogel implant, the company's lead product for the treatment of advanced heart failure (HF). Classified in Europe and in the U.S. as a medical device, Algisyl-LVR is intended to reverse HF progression in people who have an enlarged left ventricle. Surgically injected directly into the heart muscle, the hydrogel acts immediately as an internal scaffold that does not undergo long-term degradation and increases cardiac output. The CE Mark indicates a product's compliance with European Union legislation and that it can be sold throughout the European Economic Area. Six-month patient outcome studies of Algisyl-LVR will be presented at the annual meeting of the American Heart Association (AHA), November 15-19, 2014 in Chicago. The AUGMENT-HF randomized clinical trial is being conducted at 14 centers in Italy, Germany, Romania, Australia, and The Netherlands to determine if the product is superior to standard medical therapy in the management of patients with a dilated and weakened left ventricle and significantly deteriorated cardiac function.
LoneStar Heart Presents at 13th Annual BIO Investor Forum, Oct-07-2014 01:30 PM
Sep 9 14
LoneStar Heart Presents at 13th Annual BIO Investor Forum, Oct-07-2014 01:30 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.
LoneStar Heart Closes Patient Enrollment in Clinical Trial of Algisyl-LVR for Advanced Heart Failure
May 6 14
LoneStar Heart has completed the patient recruitment Phase of its AUGMENT-HF controlled randomized trial of its lead product Algisyl-LVR hydrogel implant for the treatment of advanced heart failure (HF). The AUGMENT-HF clinical trial is being carried out at 14 centers in Italy, Germany, Romania, Australia, and The Netherlands and its six-month outcomes are expected to be reported by the end of 2014. The trial is designed to determine if the product is superior to standard medical therapy in the management of patients with a dilated and weakened left ventricle and significantly deteriorated cardiac function. Interim results of the trial showed left ventricle augmentation of the failing heart after implantation with Algisyl-LVR can be performed safely in patients with advanced heart failure and provides functional improvement in their health status.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|